Expression level of a pancreatic neo-antigen in beta cells determines degree of diabetes pathogenesis

Journal of Autoimmunity

Volumn 35, Issue 4, 2010, Pages 404-413

  Martinic, Marianne M ^a   Huber, Christoph ^b   Coppieters, Ken ^a   Oldham, Janine E ^a   Gavin, Amanda L ^b   von Herrath, Matthias G ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmune diabetes; Immunomodulation; Lymphocytic choriomeningitis virus glycoprotein; T cells; Tolerance; Transgenic mice

Indexed keywords

ANTIGEN; AUTOANTIGEN; BETA ACTIN; CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; DIABETOGENESIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, VIRAL; ARENAVIRIDAE INFECTIONS; AUTOANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CROSS-PRIMING; CYTOTOXICITY, IMMUNOLOGIC; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; GLYCOPROTEINS; INSULIN-SECRETING CELLS; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL;

EID: 77958152283     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2010.08.006     Document Type: Article

References (64)

1. Bach J.F. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994, 15:516-542.
2. Wucherpfennig K.W., Eisenbarth G.S. Type 1 diabetes. Nat Immunol 2001, 2:767-768.
3. Liu E., Eisenbarth G.S. Type 1A diabetes mellitus-associated autoimmunity. Endocrinol Metab Clin North Am 2002, 31:391-410. vii-viii.
4. Roep B.O. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia 2003, 46:305-321.
5. Chatenoud L., Thervet E., Primo J., Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994, 91:123-127.
6. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54:1763-1769.
7. Bresson D., von Herrath M. Moving towards efficient therapies in type 1 diabetes: to combine or not to combine?. Autoimmun Rev 2007, 6:315-322.
8. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315:115-122.
9. Ohashi P.S., Oehen S., Buerki K., Pircher H., Ohashi C.T., Odermatt B., et al. Ablation of " tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991, 65:305-317.
10. Oldstone M.B., Nerenberg M., Southern P., Price J., Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991, 65:319-331.
11. + T cells. Eur J Immunol 1992, 22:1013-1022.
12. Kurts C., Heath W.R., Carbone F.R., Allison J., Miller J.F., Kosaka H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996, 184:923-930.
13. Blanas E., Carbone F.R., Allison J., Miller J.F., Heath W.R. Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996, 274:1707-1709.
14. Akkaraju S., Ho W.Y., Leong D., Canaan K., Davis M.M., Goodnow C.C. A range of CD4 T cell tolerance: partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis. Immunity 1997, 7:255-271.
15. Kurts C., Miller J.F., Subramaniam R.M., Carbone F.R., Heath W.R. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998, 188:409-414.
16. Byersdorfer C.A., Schweitzer G.G., Unanue E.R. Diabetes is predicted by the beta cell level of autoantigen. J Immunol 2005, 175:4347-4354.
17. Heath W.R., Allison J., Hoffmann M.W., Schonrich G., Hammerling G., Arnold B., et al. Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature 1992, 359:547-549.
18. Kurts C., Kosaka H., Carbone F.R., Miller J.F., Heath W.R. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 1997, 186:239-245.
19. Kurts C., Sutherland R.M., Davey G., Li M., Lew A.M., Blanas E., et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A 1999, 96:12703-12707.
20. Scott B., Liblau R., Degermann S., Marconi L.A., Ogata L., Caton A.J., et al. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1994, 1:73-83.
21. + T cells specific for a pancreatic beta cell neo-antigen. Immunity 1995, 2:573-585.
22. Morgan D.J., Liblau R., Scott B., Fleck S., McDevitt H.O., Sarvetnick N., et al. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol 1996, 157:978-983.
23. Skowera A., Ellis R.J., Varela-Calvino R., Arif S., Huang G.C., Van-Krinks C., et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008, 118:3390-3402.
24. Oxenius A., Bachmann M.F., Zinkernagel R.M., Hengartner H. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur J Immunol 1998, 28:390-400.
25. Pircher H., Burki K., Lang R., Hengartner H., Zinkernagel R.M. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 1989, 342:559-561.
26. Calzascia T., Pellegrini M., Lin A., Garza K.M., Elford A.R., Shahinian A., et al. CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc Natl Acad Sci U S A 2008, 105:2999-3004.
27. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
28. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
29. von Herrath M.G., Guerder S., Lewicki H., Flavell R.A., Oldstone M.B. Coexpression of B7-1 and viral (" self" ) transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. Immunity 1995, 3:727-738.
30. Garza K.M., Chan S.M., Suri R., Nguyen L.T., Odermatt B., Schoenberger S.P., et al. Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med 2000, 191:2021-2027.
31. Millar D.G., Garza K.M., Odermatt B., Elford A.R., Ono N., Li Z., et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat Med 2003, 9:1469-1476.
32. Lang K.S., Recher M., Junt T., Navarini A.A., Harris N.L., Freigang S., et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005, 11:138-145.
33. Martinic M.M., von Herrath M.G. Real-time imaging of the pancreas during development of diabetes. Immunol Rev 2008, 221:200-213.
34. von Herrath M.G., Dockter J., Oldstone M.B. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1994, 1:231-242.
35. Weaver R. Molecular biology 2007, McGraw Hill Higher Education, Boston. 4th ed.
36. Weber E.L., Buchmeier M.J. Fine mapping of a peptide sequence containing an antigenic site conserved among arenaviruses. Virology 1988, 164:30-38.
37. Buchmeier M.J., Oldstone M.B. Protein structure of lymphocytic choriomeningitis virus: evidence for a cell-associated precursor of the virion glycopeptides. Virology 1979, 99:111-120.
38. Burns J.W., Buchmeier M.J. Protein-protein interactions in lymphocytic choriomeningitis virus. Virology 1991, 183:620-629.
39. Ludewig B., Odermatt B., Landmann S., Hengartner H., Zinkernagel R.M. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med 1998, 188:1493-1501.
40. + T cells is transient and depends on avidity. J Immunol 1995, 155:2339-2349.
41. Garza K.M., McKall-Faienza K.J., Otheki T., Zakarian A., Odermatt B., Ohashi P.S. Enhanced T cell responses contribute to the genetic predisposition of CD8-mediated spontaneous autoimmunity. Eur J Immunol 2002, 32:885-894.
42. Shigihara T., Oikawa Y., Kanazawa Y., Okubo Y., Narumi S., Saruta T., et al. Significance of serum CXCL10/IP-10 level in type 1 diabetes. J Autoimmun 2006, 26:66-71.
43. Martinic M.M., Juedes A.E., Bresson D., Homann D., Skak K., Huber C., et al. Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD mice. Diabetes 2007, 56:1059-1068.
44. Ramanathan S., Dubois S., Gagnon J., Leblanc C., Mariathasan S., Ferbeyre G., et al. Regulation of cytokine-driven functional differentiation of CD8 T cells by suppressor of cytokine signaling 1 controls autoimmunity and preserves their proliferative capacity toward foreign antigens. J Immunol 2010, 185:357-366.
45. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med 1997, 186:2057-2062.
46. Behrens G.M., Li M., Davey G.M., Allison J., Flavell R.A., Carbone F.R., et al. Helper requirements for generation of effector CTL to islet beta cell antigens. J Immunol 2004, 172:5420-5426.
47. + T reg cells impinge on autoimmune diabetes. J Exp Med 2005, 202:1387-1397.
48. Tang Q., Bluestone J.A. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 2006, 212:217-237.
49. + regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 2007, 204:191-201.
50. von Herrath M. Can we learn from viruses how to prevent type 1 diabetes?: the role of viral infections in the pathogenesis of type 1 diabetes and the development of novel combination therapies. Diabetes 2009, 58:2-11.
51. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010, 11:7-13.
52. Ehl S., Hombach J., Aichele P., Hengartner H., Zinkernagel R.M. Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med 1997, 185:1241-1251.
53. Homann D., Holz A., Bot A., Coon B., Wolfe T., Petersen J., et al. Autoreactive CD4 T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 1999, 11:463-472.
54. Pechhold K., Karges W., Blum C., Boehm B.O., Harlan D.M. Beta cell-specific CD80 (B7-1) expression disrupts tissue protection from autoantigen-specific CTL-mediated diabetes. J Autoimmun 2003, 20:1-13.
55. Podojil J.R., Miller S.D. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol Rev 2009, 229:337-355.
56. Seewaldt S., Thomas H.E., Ejrnaes M., Christen U., Wolfe T., Rodrigo E., et al. Virus-induced autoimmune diabetes: most beta-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) cytotoxic T-lymphocytes. Diabetes 2000, 49:1801-1809.
57. Christen U., McGavern D.B., Luster A.D., von Herrath M.G., Oldstone M.B. Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J Immunol 2003, 171:6838-6845.
58. Christensen J.E., de Lemos C., Moos T., Christensen J.P., Thomsen A.R. CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. J Immunol 2006, 176:4235-4243.
59. Spolski R., Kashyap M., Robinson C., Yu Z., Leonard W.J. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A 2008, 105:14028-14033.
60. + T cells. J Exp Med 2008, 205:1019-1027.
61. Sutherland A.P., Van Belle T., Wurster A.L., Suto A., Michaud M., Zhang D., et al. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009, 58:1144-1155.
62. von Herrath M.G., Fujinami R.S., Whitton J.L. Microorganisms and autoimmunity: making the barren field fertile?. Nat Rev Microbiol 2003, 1:151-157.
63. Russell W.L., Kelly E.M., Hunsicker P.R., Bangham J.W., Maddux S.C., Phipps E.L. Specific-locus test shows ethylnitrosourea to be the most potent mutagen in the mouse. Proc Natl Acad Sci U S A 1979, 76:5818-5819.
64. Beutler B., Jiang Z., Georgel P., Crozat K., Croker B., Rutschmann S., et al. Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006, 24:353-389.